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PrevalenceThis study compared the effectiveness of the community-wide treatment and school-based treatment
approaches in the control of Schistosoma mansoni infections in villages withP25% prevalence in western
Kenya. Stool samples from first year students, 9–12 year olds and adults (20–55 years) were analyzed by
the Kato–Katz technique for S. mansoni eggs. After two rounds of treatment, S. mansoni prevalence and
intensity levels significantly declined in both treatment approaches. Prevalence comparisons between
the two approaches did not show any significant differences following treatment. However, infection
intensity levels in the 9–12 year old school-attending pupils were significantly higher in the
community-wide treatment arm than in the school-based treatment arm. Nevertheless, significant reduc-
tions in S. mansoni infection prevalence and intensity levels were achieved among school-age children
regardless of the treatment approach used.
Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Schistosomiasis remains one of the most important water-
based diseases in the world, with an estimated 247 million people
infected in 74 countries, 85% of whom are living in sub-Saharan
Africa (World Health Organization, 1993, 2002; Chan et al., 1994;
Chitsulo et al., 2000). In Kenya, over 6.14 million people are esti-
mated to have schistosomiasis with the highest infection rates
found in adolescents (Grzych et al., 1987; Karanja et al., 1997,
1998). Overall, the prevalence of schistosomiasis in endemic areas
of Kenya ranges from 5% to 100%, contributes to significant mor-
bidity (Ouma et al., 2001; Mwinzi et al., 2004; Odiere et al.,
2012; Samuels et al., 2012) and is very high along the shores of
Lake Victoria (Handzel et al., 2003; Standley et al., 2010). Morbidity
associated with schistosomiasis includes under-nutrition, anaemia,
chronic pain, diarrhea, exercise intolerance, growth stunting and
cognitive impairment (Booth and Bundy, 1992; Stephenson et al.,
2000). Much of the morbidity is reversible and can be controlledwith treatment using praziquantel (PZQ) (Taylor-Robinson et al.,
2007; Keiser and Utzinger, 2008).
Prevalence and intensity of infection are the key indicators cur-
rently used to measure the burden of schistosome infection in a
given community. The number of eggs per gram (EPG) of feces pro-
vides a relative measure of infection intensity and is a key indicator
of transmission dynamics within communities as well as the risk of
morbidity among individuals (Anderson and May, 1985). Assess-
ment of infection intensity requires quantitative laboratory meth-
ods that are time consuming. Prevalence of infection is the more
easily collected indicator and is used by the World Health Organi-
zation (WHO) to provide guidelines for scope and frequency of
mass treatment with PZQ (World Health Organization, 2013).
PZQ is an effective, safe, single-dose treatment for schistosomiasis
with few adverse events in uninfected individuals, making it
appropriate for mass drug administration (MDA) for schistosomia-
sis control (Danso-Appiah et al., 2008).
In 2001, the 54th World Health Assembly endorsed resolution
54.19 to promote preventive measures, ensure treatment and
mobilize resources for the control of schistosomiasis and
soil-transmitted helminths (STHs) (Kabatereine et al., 2006). This
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governments in endemic regions to control schistosomiasis and
other neglected tropical diseases (NTDs) and to establish national
action plans. Examples include Uganda and Tanzania in 2003
(Guyatt et al., 2001; Kabatereine et al., 2006, 2007). In these coun-
tries, the main strategy for the delivery of anthelmintics was
through the school system, an approach that reduces both infec-
tion and morbidity in a cost-effective manner as well as enhances
educational outcomes in the treatment area (Guyatt et al., 2001;
Miguel and Kremer, 2004; Kabatereine et al., 2007). However,
treating only school children leaves out other members in the com-
munity who are also at risk of morbidity from infection and who
could contribute to continued transmission. This includes out-of-
school children, older children and adults as well as
occupationally-exposed groups like car washers, sand harvesters,
fishermen and fish handlers (Webbe and El Hak, 1990; Karanja
et al., 1997, 1998).
To also provide treatment for these groups, a community-based
approach, where all members of the community are targeted for
treatment, could be used. A multi-country study on community
directed intervention (CDI) for onchocerciasis control demon-
strated that community-based drug distribution can be effective
and feasible for integrated delivery of different health interven-
tions in rural Africa (Massa et al., 2009a,b). However, direct com-
parison studies of school and community based approaches or
combination strategies in different settings have not been per-
formed, particularly in Kenya. Data are needed to inform the most
effective control strategies and provide evidence for the most cost
efficient deworming frequencies, for example, how often MDA
should be conducted.
It is in this context that we are working with the Schistosomia-
sis Consortium for Operational Research and Evaluation (SCORE) to
evaluate different MDA approaches with PZQ in areas of western
Kenya with high prevalence (P25%) of Schistosoma mansoni infec-
tions in school age children. In a 5 year study, PZQ is delivered
either through school-based treatment (SBT) or community-wide
treatment (CWT). The two approaches involve regimens of drug
treatment with varying treatment frequency. We report changes
in S. mansoni prevalence and egg intensity levels after two rounds
of MDA with reported treatment coverage rates. From the experi-
ence of two rounds of MDA, we also gained insight on how to
improve MDA delivery.2. Materials and methods
2.1. Study site, population and design
This study was conducted in eight districts in Nyanza province
stretching approximately 300 km along the Kenyan shores of Lake
Victoria. A total of 150 villages lying within 5 km of the lake shore
were enrolled. Over 96% of the population in the study area are
members of the Luo community. Although fishing is the main com-
mercial activity in the villages, the majority of the residents are
subsistence farmers. All residents in the area are at risk of infection
with schistosomiasis due to frequent water contact in Lake Victo-
ria. No PZQ MDA activities had been conducted in the area prior
to 2011 when the study was initiated as the Kenya national pro-
gram had yet to implement PZQ distribution. However, one alben-
dazole MDA for STHs had been conducted in 2009.
Following an eligibility survey of 13–14 year olds to identify vil-
lages with P25% prevalence, 150 communities were selected and
randomised into one of six study arms, 25 villages per arm
(Fig. 1). In arms 1–3 (CWT), community health workers (CHWs)
were used to distribute drugs by going house-to-house each year
during April, which is the school vacation period when studentsare most likely to be at home. CHWs provided PZQ for all persons
who were eligible (>4 years of age and/or >94 cm tall). For persons
who were present in the home, CHWs directly observed treatment.
For persons who were not at home, the appropriate number of
tablets were left. In arms 4–6 (SBT), health teachers were engaged
to deliver PZQ to the children during February and March of each
year and directly observed the students swallowing the treatment.
Efforts were made to invite school age children who were not
attending school to also participate in the MDA.
2.2. Study approval and involvement
The study was reviewed and approved by the National Scientific
and Ethical Review Committees (ERC) of the Kenya Medical
Research Institute (KEMRI) and the Institutional Review Board of
the Centers for Disease Control and Prevention, USA, which
deferred to the KEMRI ERC. Permission to conduct the study was
obtained from the Ministry of Education, Ministry of Public Health
and Sanitation and the Nyanza Provincial Administration, Kenya.
Sensitisation of community members and school teachers was con-
ducted to explain the purpose of the study and to gain support to
test school children and adults in the community. CHWs and
school health teachers were invited to training workshops where
they were instructed in the collection of stool, use of the treatment
dose pole, how to maintain drug administration records, and how
to recognise serious adverse events (SAEs) associated with treat-
ment. Consent documents and participation information were pro-
vided to potential participants in the language they understood
best (English or Dholuo). Consent and assent for study participa-
tion and treatment were obtained from the parents or guardians
and from the children, respectively.
2.3. Parasitological assessment
For the baseline assessment, 100 randomly selected 9–12 year
old pupils and 100 first year students (children attending their first
year of schooling) in each village were requested to provide stool
samples. The 9–12 year olds provided three stool samples on three
consecutive days while the first year students provided only one
stool sample. In each community, 50 adults were randomly
selected and, following enrollment and informed consent, asked
to provide one stool sample. A greater number of samples were
obtained from 9 to 12 year olds because the main goal of the study
was to assess the impact of different MDA strategies on this age
group. Sampling of first year students was performed to test if
the MDA approaches had different impacts on the force of trans-
mission and adults were sampled to monitor for any global
changes that may be affecting the study village. However, as these
were secondary questions and resources were limited, only one
stool sample was collected from first year students and adults.
Similarly, while stool samples were obtained from 9 to 12 year
old students every year, according to the harmonised SCORE proto-
col, first year student and adult samples were only scheduled for
the first (baseline), third (after two treatments), and fifth (after
four treatments) years of the study. Each participant was issued
empty stool cups and other sanitary necessities such as tissue
paper and a scoop-stick, and the procedure for safe stool collection
was explained. Stool sample collection took place over the course
of 1 week in any one school or community by a team of one to
two technicians with the help of a health teacher or CHW.
Stool samples were then transported to laboratories at KEMRI
Center for Global Health Research (KEMRI-CGHR) and the Ministry
of Health’s Division of Vector-Borne Diseases (DVBD) laboratory,
Kisumu, where they were processed. Each stool sample was
analyzed in duplicate by the Kato–Katz technique for eggs of
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Fig. 1. Schistosomiasis Consortium for Operational Research and Evaluation study design. Communities were randomised into six intervention arms. CWT, community-wide
treatment; SBT, school-based treatment. ND, not done, indicating that stool samples were not collected for that arm because there was no treatment scheduled for that year.
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and egg data were recorded in booklets. After baseline stool sample
collection in year 1, MDA with PZQ was conducted. In year 2, stool
samples (three per participant) were only collected from 9 to
12 year olds in the village schools, and only in Arms 1–5 as Arm
6 was not receiving treatment that year. In year 3, stool samples
were collected from first year students, 9–12 year olds, and adults
in arms 1 and 2 (CWT) and from first year students and 9–12 year
olds in Arms 4 and 6 (SBT). In years 2 and 3, new random samples
of pupils and adults were recruited and requested to provide con-
sent/assent to be evaluated for S. mansoni and STH infection. Stool
collection, Kato–Katz slide preparation and microscopic examina-
tion to determine egg counts were performed as in the baseline
survey.
2.4. MDA with PZQ and treatment coverage assessment
Treatment with PZQ as a single dose of 40 mg/kg was delivered
using the WHO dose pole (Montresor et al., 2001). Usual WHO PZQ
treatment exclusion criteria were applied: children under 4 years
of age or under 94 cm in height were not treated. In villages receiv-
ing CWT, drugs were distributed door-to-door by CHWs during
school holidays in an attempt to treat all members of the commu-
nity. Consent to include a home compound in the treatment was
sought from the compound head, but individuals were free to
decline treatment. From the population census conducted by the
CHWs, coverage in CWT villages was estimated by comparing the
number of people (both adults and school age children) who
received PZQ as recorded by CHWs with the eligible population
in that particular village.
To evaluate coverage reported by CHWs, the study team con-
ducted a household survey in all 75 villages in the CWT arms in
the second year of the study. A list of households in a particular vil-
lage was obtained from the population census earlier conducted by
the CHWs in all CWT villages. Average village size was shown to be
approximately 198 households, with the smallest village consisting
of 40 households and the largest village consisting of 1200 house-
holds. In estimating treatment coverage in a particular village, the
households were first ranked randomly, and depending on the size
of the village, 15 or 30 households were selected for the household
survey. Treatment coverage was then determined as the propor-
tion of people (both adults and school age children) who reportedthey received PZQ compared with the total eligible population of
the selected households in a particular village.
For villages assigned to SBT, primary school pupils were admin-
istered PZQ by trained school health teachers. The names of chil-
dren who received PZQ were recorded in the treatment booklets
and their number compared against the school enrollment list/eli-
gible population to estimate treatment coverage.
According to SCORE goals, we targeted treatment coverage of
P90% in SBT arms and at least 75% in CWT arms. CHWs and school
health teachers documented treatment coverage and reasons for
the success or failure to meet the targeted coverage rate in treat-
ment booklets. The information was then collected during CHW
and health teacher feedback sessions.
2.5. Data collection and analysis
Field data were collected using barcoded master lists in which
age, sex, class, school, village, parental consent and child assent,
and number of stool samples and respective collection dates were
recorded. In the laboratory, egg data were recorded in barcoded
results booklets. Consistent with WHO guidelines, individuals with
EPG <100 were considered to have low intensity infections, those
with 100–400 EPG were considered to have moderate intensity
infections, and persons with >400 EPG were considered to have
high intensity infections. MDA data were recorded in treatment
and drug tracking books. All the data from master lists and results
booklets were then entered into smart phones installed with
EpiCollect software for submission to the central server hosted at
the Imperial College, London, UK. Data were also entered in Micro-
soft Excel spreadsheets and maintained on local desktop comput-
ers for back-up and analysis purposes.
Prevalence was assessed using a generalised linear model
(GLM) with generalised estimating equations (GEE) (Liang and
Zeger, 1986) to account for correlation between participants from
the same community or school. Study arm, year and an interaction
between the two were included as independent variables. A Pois-
son distribution was assumed for the outcome, allowing for results
to be reported as prevalence ratios (PR).
Similar to the prevalence models, a GLM with GEE was used to
model infection intensity. A gamma distribution was found to best
match the EPG distribution, especially since infected and non-
infected participants were included in the model. One was added
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only defined for positive real numbers. This was then subtracted
from the final parameter estimates. Comparisons are reported as
arithmetic mean ratios (AMR), a ratio of the two estimated mean
EPGs in the comparison.
All statistical analyses were performed in SAS version 9.3 (SAS
Institute, Inc., Cary, NC, USA) using PROC GENMOD and the 5% level
of significance. Where appropriate, post-hoc contrasts were used
to estimate prevalence or intensity and make year to year compar-
isons in single or across multiple arms.3. Results
3.1. MDA treatment coverage in first and second rounds of treatment
Table 1 summarises treatment coverage as reported by the
CHWs and health teachers and from the household survey in year
2. In the CWT arm, 75 villages participated in both rounds of treat-
ment. In the first round, CHWs reported having given treatment to
24,118 people out of an eligible population of 28,694, representing
a coverage rate of 84.1% (95% confidence interval (CI) = 83.2–
89.4%). In the second round, they reported treatment of 25,399
people out of an eligible population of 29,011 representing a cov-
erage rate of 87.6% (95% CI = 85.3–91.1%). In both rounds of treat-
ment, 65 (86.7%) villages achieved the 75% treatment coverage
mark. The independent household survey, conducted after the sec-
ond round of treatment, revealed that treatment was given to a
total of 3781 people out of an eligible population of 6055, repre-
senting a coverage rate of 62.4% (95% CI = 58.7–67.2%) with only
25 (33.3%) villages attaining P75% coverage.
In the SBT arms, 75 and 51 villages were scheduled for the first
and second rounds of treatment, respectively. In the first year,
treatmentwas given to 22,406 school-age children out of an eligible
population of 26,487, representing a treatment coverage of 84.6%
(95% CI = 82.9–87.0%). In the second round, treatment was given
to 15,984 school age children out of an eligible population of
17,796 representing a coverage rate of 89.8% (95% CI = 86.2–91.4).Table 1
Mass drug administration coverage in first and second rounds of treatment with praziqua
Treatment round Arm No. of villages
surveyed (n)
Eligible population Num
First round CWT 75 28,694 24,11
SBT 75 26,487 22,40
Second round CWT 75 29,011 25,39
SBT 51 17,796 15,98
Household Survey 75 6055 3781
CWT, community wide treatment; SBT, school based treatment; CI, confidence interval.
a Coverage as reported by community health workers (CWT arms) or teachers (SBT a
b Coverage determined by the household survey.
Table 2
Schistosoma mansoni infection prevalence and intensity levels in years 1–3 in community
Study year Study group Study arms Preva
CWT SBT CWT
2011 First year students 1, 2, 3 4, 5, 6 26 (2
9–12 years 1, 2, 3 4, 5, 6 60 (5
Adults 1, 2, 3 4, 5, 6 42 (3
2012 9–12 years 1, 2, 3 4, 5 51 (4
2013 First year students 1 4 21 (1
9–12 years 1 4 48 (3
Adults 1 – 16 (1
CI, confidence interval; EPG, eggs per gram.In the first and second rounds of treatment, 28 (37.3%) and 22
(43.1%) schools achieved the 90% treatment coverage goal.3.2. Schistosoma mansoni infection prevalence and intensity in years
1–3 in CWT and SBT
Prevalence and intensity data for S. mansoni infections are pre-
sented in Table 2 and relative changes over time are shown in
Table 3. Comparison of baseline data indicated that there were
no significant differences between the arms or treatment strate-
gies, indicating that the randomisation was effective (data not
shown). Not surprisingly, the highest infection levels occurred in
9–12 year olds, followed by the adults and the first year students.
Among 9–12 year olds, significantly lower prevalence levels were
recorded in year 2 than in year 1 both in the CWT (PR = 0.85, 95%
CI = 0.80–0.90, P < 0.001) and SBT (PR = 0.71, 95% CI = 0.66–0.78,
P < 0.001) arms. Similarly, year 3 prevalence levels in all the study
groups were significantly lower than those in year 1 for both treat-
ment approaches (9–12 year olds (CWT (PR = 0.77, 95% CI = 0.67–
0.88, P < 0.001, and SBT PR = 0.56, 95% CI = 0.47–0.67, P < 0.001),
first year students (CWT PR = 0.61, 95% CI = 0.47–0.79, P < 0.001
and SBT PR = 0.65, 95% CI = 0.48–0.87, P = 0.004) and adults (CWT
PR = 0.37, 95% CI = 0.28–0.47, P < 0.001)). Comparisons between
year 3 and year 2 prevalence levels were only done in the 9–
12 year olds and only the CWT arm recorded significantly lower
prevalence levels in year 3 than year 2, PR = 0.84, 95% CI = 0.76–
0.93, P < 0.001. For the intensity comparisons, in the 9–12 year
olds, only the SBT arm recorded significantly lower intensity levels
in year 2 than those in year 1, AMR = 0.46, 95% CI = 0.41–0.52,
P < 0.001. However, both treatment approaches recorded signifi-
cantly lower infection intensity levels in year 3 than those in year
1 (CWT AMR = 0.77, 95% CI = 0.62–0.94, P = 0.01, and SBT
AMR = 0.37, 95% CI = 0.27–0.51, P < 0.001). However, first year stu-
dents and the adult categories’ infection intensity levels in year 3
were only significantly lower in the CWT armwhen compared with
those in year 1 (first year students AMR 8 0.60, 95% CI = 0.41–0.89,
P = 0.01 and adults AMR = 0.42, 95% CI = 0.26–0.67, P < 0.001).
Comparisons between years 3 and 2 intensity levels included onlyntel.
ber treated Coverage (%) 95% CI Villages with P75% CWT
or P90% SBT coverage, n (%)
8 84.1a 83.2–89.4 65 (86.7)a
6 84.6a 82.9–87.0 28 (37.3)a
9 87.6a 85.3–91.1 65 (86.7)a
4 89.8a 86.2–91.4 22 (43.1)a
62.4b 58.7–67.2 25 (33.3)b
rms);
wide treatment and school based treatment (SBT) arms.
lence (95% CI) Mean EPG (95% CI)
SBT CWT SBT
1–33) 29 (24–35) 53.0 (36.1–77.6) 54.1 (37.4–78.1)
5–66) 63 (58–68) 88.5 (70.0–111.9) 91.6 (72.1–116.4)
8–47) 46 (41–50) 61.7 (50.7–75.1) 73.0 (59.4–89.5)
6–57) 45 (38–52) 79.3 (59.1–106.1) 41.0 (29.7–56.6)
4–32) 18 (12–28) 45.6 (25.3–81.5) 32.3 (16.3–79.6)
8–61) 34 (25–45) 76.9 (49.4–119.3) 31.8 (18.4–54.4)
2–22) – 22.5 (12.2–40.8) –
Table 3
Prevalence and intensity comparisons between study years in community wide treatment and school based treatment arms.
Study group Years compared Study arm Individual arms compared PR (95% CI) P value AMR (95% CI) P value
9–12 years 2012 vs. 2011 CWT 1, 2, 3 vs. 1, 2, 3 0.85 (0.80–0.90) <0.001 0.90 (0.78–1.03) 0.12
SBT 4, 5 vs. 4, 5, 6 0.71 (0.66–0.78) <0.001 0.46 (0.41–0.52) < 0.001
2013 vs. 2011 CWT 1 vs. 1, 2, 3 0.77 (0.67–0.88) <0.001 0.77 (0.62–0.94) 0.01
SBT 4 vs. 4, 5, 6 0.56 (0.47–0.67) <0.001 0.37 (0.27–0.51) < 0.001
2013 vs. 2012 CWT 1 vs. 1, 2, 3 0.84 (0.76–0.93) <0.001 0.77 (0.62–0.95) 0.01
SBT 4 vs. 4, 5 0.88 (0.75–1.03) 0.12 0.83 (0.57–1.22) 0.35
First year students 2013 vs. 2011 CWT 1 vs. 1, 2, 3 0.61 (0.47–0.79) <0.001 0.60 (0.41–0.89) 0.01
SBT 4 vs. 4, 5, 6 0.65 (0.48–0.87) 0.004 0.79 (0.34–1.82) 0.58
Adults 2013 vs. 2011 CWT 1 vs. 1, 2, 3 0.37 (0.28–0.47) <0.001 0.42 (0.26–0.67) <0.001
PR, prevalence ratio; AMR, arithmetic mean ratio; CI, confidence interval.
Table 4
Prevalence and intensity comparisons between community wide treatment and School based treatment arms in each study year.
Study year Study group Arms compared PR (95% CI) P value AMR (95% CI) P value
CWT SBT
2011 First year students 1, 2, 3 4, 5, 6 0.90 (0.68–1.20) 0.48 0.98 (0.58–1.65) 0.94
9–12 years 1, 2, 3 4, 5, 6 0.96 (0.85–1.08) 0.51 0.97 (0.69–1.35) 0.84
Adults 1, 2, 3 4, 5, 6 0.93 (0.81–1.06) 0.27 0.85 (0.64–1.12) 0.25
2012 9–12 years 1, 2, 3 4, 5 1.15 (0.95–1.38) 0.15 1.91 (1.25–2.93) 0.003
2013 First year students 1 4 1.14 (0.62–2.10) 0.67 1.25 (0.48–3.26) 0.65
9–12 years 1 4 1.42 (0.99–2.05) 0.06 2.37 (1.20–4.69) 0.01
PR, prevalence ratio; AMR, arithmetic mean ratio; CI, confidence interval.
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lower infection intensity levels in year 3 than in year 2
(AMR = 0.77, 95% CI = 0.62–0.95, P = 0.01).
3.3. Prevalence and intensity comparisons between CWT and SBT arms
in each study year
Although schistosomiasis prevalence levels were generally
lower in the SBT arms after treatment in all age groups, compar-
isons of the prevalence levels among the 9–12 year olds between
the CWT arms and the SBT arms did not show any significant dif-
ferences across the three years of the study (Table 4). Similarly,
in the first year students and adults, no significant differences were
observed between the two treatment approaches at baseline for
either age group or in year 3 for the first year students. The inten-
sity levels in the 9–12 year olds were not significantly different
between the two treatment approaches at baseline but in both
years 2 and 3, the intensity levels were significantly higher in the
CWT arms than in the SBT arms (year 2 AMR = 1.91, 95%
CI = 1.25–2.93, P = 0.003, and year 3 AMR = 2.37, 95% CI = 1.20–
4.69, P = 0.01). For the first year students and adults, the infection
intensity levels were not significantly different between the two
treatment approaches at baseline or for the first year students in
year 3.
4. Discussion
Depending on the prevalence of schistosomiasis infection in a
given community, WHO recommends MDA delivery using either
a school-based or community-wide approach. In this study, the
effectiveness of SBT and CWT was compared for the control of S.
mansoni infections in villages with an initial prevalenceP25%. Par-
asitological assessment following two rounds of treatment
revealed that both CWT and SBT treatment approaches had a sig-
nificant impact on the prevalence and intensity of schistosomiasis.
Comparisons of the effect on prevalence between the two
approaches did not show any significant differences. Thus, SBT
and CWT were equally effective in reducing the prevalence of S.mansoni. By contrast, the SBT arms demonstrated significantly
higher reductions in infection intensity than the CWT arms after
1 and 2 treatments among 9–12 year olds.
A number of villages failed to attain the targets set by the SCORE
protocol, even after follow-up treatment efforts in areas that had
earlier recorded low treatment coverage. Although the CHWs’
reports indicated the CWT arm had higher coverage than the SBT
arm, assessing coverage was problematic in the CWT villages as
artificially high coverage rates were reported by the CHWs. This
was partly due to the fact that the CHWs had conducted a census
ahead of the treatment exercise and used those data to estimate
coverage from their records; however, in some cases the census
was not necessarily based on all compounds in villages, depending
on the diligence of the CHW.
Some of the factors that might have influenced the increased
impact on infection intensity in the SBT arm include that children
in schools are already congregated, higher compliance during
screening and treatment may be linked to direct supervision by
school health teachers, (Guyatt and Tanner, 1996) and efforts to
conduct follow-up treatments to reach those who were absent dur-
ing the initial treatment exercise are more efficient. However,
some schools recorded coverage rates that were less than the
SCORE protocol target. Factors that contribute to lower coverage
in such schools should be evaluated to assist in development of
approaches to improve coverage for better control of schistosomi-
asis (Touré et al., 2008).
When we visited the schools in the CWT arms for parasitologi-
cal assessment in the second year of the study, some teachers
questioned why certain students had not received treatment in
the community drug distribution. To address this concern, a house-
hold survey was conducted after the second round of treatment. It
revealed that actual coverage rates and the number of villages with
P75% treatment coverage in the CWT arms were significantly
lower than what had been reported by the CHWs and that treat-
ment coverage in the CWT arms may have been substantially lower
than that in the SBT arms. Thus, the higher apparent impact of SBT
on infection intensity compared with CWT may simply be a func-
tion of the treatment coverage challenges in the CWT arm.
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ing community members, lack of supervision during treatment
and the fact that this was the first MDA in this area are some of
the reasons that might explain the lower performance in the
CWT arm. A similar scenario was reported in the Philippines where
village leaders were primarily responsible for community mobili-
sation and the extent of their support for the program was unclear
and possibly incomplete, as less than 50% coverage was achieved
(Tallo et al., 2008). Many studies have shown significant differ-
ences between reported coverage and household survey coverage
rates (Mwinzi et al., 2012). Use of the reported treatment coverage
data with the possibility of exaggeration by the CHWs and health
teachers constitutes a major limitation in our study as acceptance
of these data at face value may have introduced bias in our find-
ings. After we identified the discrepancies between the reported
coverage and household survey data in the CWT arms, CHW train-
ing prior to the next round of MDA focused on improved data col-
lection and accurate reporting of coverage rates. This included
public education and awareness efforts aimed at community
mobilisation conducted before commencement of MDAs, such as
radio announcements, road shows, notices and barazas (commu-
nity gatherings convened by the village chief) (Omedo et al.,
2014). Treatment coverage rates attained in our study differ from
coverage reported with studies conducted in Uganda
(Ndyomugyenyi and Kabatereine, 2003), and Tanzania (Massa
et al., 2009a), where higher treatment coverage rates were
achieved in the community approach compared with the school
approach, indicating that treatment compliance levels may differ
among countries. Further qualitative research in our study is ongo-
ing to identify treatment compliance issues at the community and
school levels and ways to improve it.
Reported impact of the two approaches, SBT compared with
CWT, on prevalence and intensity of schistosomiasis has not been
consistent across studies or countries. Our findings on the reduc-
tion in schistosomiasis prevalence and intensity levels differed
from studies conducted in Uganda (Zhang et al., 2007) and Burkina
Faso (Touré et al., 2008). In these two countries, the effect of PZQ
treatment using the CWT approach was greater than using the
SBT approach. However, our findings match those of another study
from Tanzania on the effectiveness of CWT as an alternative
approach for MDA delivery (Massa et al., 2009b).
In conclusion, our midterm evaluation findings from this 5 year
study indicate that significant reductions in schistosomiasis preva-
lence and intensity levels were achieved regardless of the treat-
ment approach used. However, the failure of some communities
to attain treatment coverage targets set by the SCORE protocol
and the threshold recommended by the WHO, together with the
finding that S. mansoni prevalence and intensity levels still
remained relatively high after two rounds of MDA, signify the need
for intensified community mobilisation for increased participation,
which will be critical to achieve better control of schistosomiasis.
In high prevalence communities, it may also be necessary to pro-
vide MDA more than once a year.
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